Targeted small molecule therapy and inhibitors for lymphoma

被引：0
作者：
Wang, Zhong-Hui [1 ]
Zheng, Xiang [1 ]
Rao, Guo-Wu [1 ]
Zheng, Quan [2 ]
机构：
[1] Zhejiang Univ Technol, Coll Pharmaceut Sci, Hangzhou 310014, Peoples R China
[2] Wenzhou Med Univ, Quzhou Affiliated Hosp, Quzhou Peoples Hosp, Core Facil, Quzhou 324000, Peoples R China
来源：
FUTURE MEDICINAL CHEMISTRY | 2024年 / 16卷 / 14期
关键词：
BTK; HDAC; inhibitor; lymphoma; PI3K delta; treatment; tumor; HISTONE DEACETYLASE INHIBITORS; CHRONIC LYMPHOCYTIC-LEUKEMIA; T-CELL LYMPHOMA; OPEN-LABEL; PHASE-II; ACALABRUTINIB ACP-196; FOLLICULAR LYMPHOMA; SINGLE-AGENT; PANOBINOSTAT; IBRUTINIB;
D O I：
10.1080/17568919.2024.2359893
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Lymphoma, a blood tumor, has become the ninth most common cancer in the world in 2020. Targeted inhibition is one of the important treatments for lymphoma. At present, there are many kinds of targeted drugs for the treatment of lymphoma. Studies have shown that Histone deacetylase, Bruton's tyrosine kinase and phosphoinositide 3-kinase all play an important role in the occurrence and development of tumors and become important and promising inhibitory targets. This article mainly expounds the important role of these target protein in tumors, and introduces the mechanism of action, structure-activity relationship and clinical research of listed small molecule inhibitors of these targets, hoping to provide new ideas for the treatment of lymphoma.
引用
收藏
页码：1465 / 1484
页数：20
相关论文
共 115 条
  • [1] Binding and selectivity studies of phosphatidylinositol 3-kinase (PI3K) inhibitors
    Al Hasan, Mohammad
    Sabirianov, Matthew
    Redwine, Grace
    Goettsch, Kaitlin
    Yang, Stephen X.
    Zhong, Haizhen A.
    [J]. JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2023, 121
  • [2] Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)
    Arora, Sukeshi Patel
    Tenner, Laura
    Sarantopoulos, John
    Morris, Jay
    Liu, Qianqian
    Mendez, Jenny A.
    Curiel, Tyler
    Michalek, Joel
    Mahalingam, Devalingam
    [J]. BRITISH JOURNAL OF CANCER, 2022, 127 (06) : 1153 - 1161
  • [3] The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL
    Balakrishnan, K.
    Peluso, M.
    Fu, M.
    Rosin, N. Y.
    Burger, J. A.
    Wierda, W. G.
    Keating, M. J.
    Faia, K.
    O'Brien, S.
    Kutok, J. L.
    Gandhi, V.
    [J]. LEUKEMIA, 2015, 29 (09) : 1811 - 1822
  • [4] Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
    Barf, Tjeerd
    Covey, Todd
    Izumi, Raquel
    van de Kar, Bas
    Gulrajani, Michael
    van Lith, Bart
    van Hoek, Maaike
    de Zwart, Edwin
    Mittag, Diana
    Demont, Dennis
    Verkaik, Saskia
    Krantz, Fanny
    Pearson, Paul G.
    Ulrich, Roger
    Kaptein, Allard
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2017, 363 (02) : 240 - 252
  • [5] Efficacy in the margins of NHL with ibrutinib
    Barr, Paul M.
    [J]. BLOOD, 2017, 129 (16) : 2207 - 2208
  • [6] An overview of molecular hybrids in drug discovery
    Berube, Gervais
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (03) : 281 - 305
  • [7] PI3K isoforms in cell signalling and vesicle trafficking
    Bilanges, Benoit
    Posor, York
    Vanhaesebroeck, Bart
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2019, 20 (09) : 515 - 534
  • [8] Differential Response of Mycosis Fungoides Cells to Vorinostat
    Bordeaux, Zachary A.
    Reddy, Sriya V.
    Lee, Kevin
    Lu, Weiying
    Choi, Justin
    Miller, Meghan
    Roberts, Callie
    Pollizzi, Anthony
    Kwatra, Shawn G.
    Kwatra, Madan M.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (09)
  • [9] Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
    Byrd, John C.
    Hillmen, Peter
    Ghia, Paolo
    Kater, Arnon P.
    Chanan-Khan, Asher
    Furman, Richard R.
    O'Brien, Susan
    Yenerel, Mustafa Nuri
    Illes, Arpad
    Kay, Neil
    Garcia-Marco, Jose A.
    Mato, Anthony
    Pinilla-Ibarz, Javier
    Seymour, John F.
    Lepretre, Stephane
    Stilgenbauer, Stephan
    Robak, Tadeusz
    Rothbaum, Wayne
    Izumi, Raquel
    Hamdy, Ahmed
    Patel, Priti
    Higgins, Kara
    Sohoni, Sophia
    Jurczak, Wojciech
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (31) : 3441 - +
  • [10] Acalabrutinib in treatment-naive chronic lymphocytic leukemia
    Byrd, John C.
    Woyach, Jennifer A.
    Furman, Richard R.
    Martin, Peter
    O'Brien, Susan
    Brown, Jennifer R.
    Stephens, Deborah M.
    Barrientos, Jacqueline C.
    Devereux, Stephen
    Hillmen, Peter
    Pagel, John M.
    Hamdy, Ahmed
    Izumi, Raquel
    Patel, Priti
    Wang, Min Hui
    Jain, Nitin
    Wierda, William G.
    [J]. BLOOD, 2021, 137 (24) : 3327 - 3338
12345678910